Jake Samuel Burrell1, Jane Halliday2, Simon Walker-Samuel3, Jessica K. R. Boult1, Yann Jamin1, John C. Waterton2, Simon P. Robinson1
1The Institute of Cancer Research, Sutton, Surrey, United Kingdom; 2AstraZeneca, Manchester, United Kingdom; 3Centre for Advanced Biomedical Imaging, UCL, London, United Kingdom
The combined carbogen USPIO (CUSPIO) imaging protocol uses two MRI biomarkers of vascular function, δR2* during carbogen breathing and δR2* after injection of USPIO particles, combined with a novel segmentation method, which provides information about their spatial co-localisation. CUSPIO imaging provides five response categories, which reflects tumour vascular function and architecture. In this study, CUSPIO imaging was applied to investigate the response of C6 rat xenografts to cediranib, an inhibitor of VEGF signalling. A decrease in fractional blood volume, and significant differences in CUSPIO response categories, were measured after treatment with cediranib.